Literature DB >> 9252196

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.

M Schmitt1, C Thomssen, K Ulm, A Seiderer, N Harbeck, H Höfler, F Jänicke, H Graeff.   

Abstract

In breast cancer, several investigations have demonstrated that the tumour biological factors uPA urokinase-type plasminogen activator) and its inhibitor PAI-1 are statistically independent, strong prognostic factors for disease-free (DFS) and overall survival (OS). However, statistical analyses performed for varying follow-up periods suggested a time variation of prognostic strength. We therefore investigated the time-dependent prognostic power of uPA, PAI-1 and steroid hormone receptor status applying the time-varying coefficient model of Gray. uPA and PAI-1 were analysed by enzyme-linked immunosorbent assay in tumour tissue extracts from 314 breast cancer patients. Hormone receptors (oestrogen and progesterone) were determined by radioligand binding or by immunohistochemistry. Univariate and multivariate analyses (Cox proportional hazards model) of DFS and OS were performed for all patients, including 147 node-negative patients. Median follow-up of patients still alive at time of analysis (n = 232) was 58 months. Although initially of high prognostic impact, a continuous decrease over time in the prognostic power of hormone receptor status and uPA was observed. In contrast, the prognostic impact of PAI-1 increased over time and reached similar strength as the lymph node status. The time-dependent risk profile of prognostic factors may have important clinical implications in regard to follow-up and patients' individual risk situation. Evaluation of time dependency of prognostic factors may also give a more profound insight into the dynamics of breast cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252196      PMCID: PMC2224071          DOI: 10.1038/bjc.1997.383

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

Authors:  S Ganesh; C F Sier; G Griffioen; H J Vloedgraven; A de Boer; K Welvaart; C J van de Velde; J H van Krieken; J H Verheijen; C B Lamers
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

2.  Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

Authors:  H Nekarda; M Schmitt; K Ulm; A Wenninger; H Vogelsang; K Becker; J D Roder; U Fink; J R Siewert
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

3.  Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.

Authors:  C F Sier; H J Vloedgraven; S Ganesh; G Griffioen; P H Quax; J H Verheijen; G Dooijewaard; K Welvaart; C J van de Velde; C B Lamers
Journal:  Gastroenterology       Date:  1994-11       Impact factor: 22.682

4.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.

Authors:  C Duggan; T Maguire; E McDermott; N O'Higgins; J J Fennelly; M J Duffy
Journal:  Int J Cancer       Date:  1995-05-29       Impact factor: 7.396

Review 5.  Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.

Authors:  N Brünner; C Pyke; C H Hansen; J Rømer; J Grøndahl-Hansen; K Danø
Journal:  Cancer Treat Res       Date:  1994

6.  Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.

Authors:  G Liu; M A Shuman; R L Cohen
Journal:  Int J Cancer       Date:  1995-02-08       Impact factor: 7.396

7.  Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

Authors:  W Kuhn; L Pache; B Schmalfeldt; P Dettmar; M Schmitt; F Jänicke; H Graeff
Journal:  Gynecol Oncol       Date:  1994-12       Impact factor: 5.482

8.  Novel methods for the determination of the angiogenic activity of human tumors.

Authors:  M Barbareschi; G Gasparini; L Morelli; S Forti; P Dalla Palma
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.

Authors:  H Kobayashi; S Fujishiro; T Terao
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

10.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

Authors:  H Pedersen; N Brünner; D Francis; K Osterlind; E Rønne; H H Hansen; K Danø; J Grøndahl-Hansen
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

View more
  12 in total

1.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Current Biomarkers for Precision Medicine in Breast Cancer.

Authors:  Soo Kyung Ahn; So-Youn Jung
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.

Authors:  J Kleeff; H Friess; P Simon; S Susmallian; P Büchler; A Zimmermann; M W Büchler; M Korc
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

4.  Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells.

Authors:  G Xiao; Y E Liu; R Gentz; Q A Sang; J Ni; I D Goldberg; Y E Shi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.

Authors:  J A Foekens; Ch Ries; M P Look; C Gippner-Steppert; J G M Klijn; M Jochum
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

6.  Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.

Authors:  P Broët; F Spyratos; S Romain; V Quillien; A Daver; G Ricolleau; A Rallet; C Toulas; B Asselain
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.

Authors:  N Harbeck; P Dettmar; C Thomssen; U Berger; K Ulm; R Kates; H Höfler; F Jänicke; H Graeff; M Schmitt
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

8.  Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.

Authors:  W Kuhn; B Schmalfeldt; U Reuning; L Pache; U Berger; K Ulm; N Harbeck; K Späthe; P Dettmar; H Höfler; F Jänicke; M Schmitt; H Graeff
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  Serum CEA and CA 15-3 as prognostic factors in primary breast cancer.

Authors:  F G Ebeling; P Stieber; M Untch; D Nagel; G E Konecny; U M Schmitt; A Fateh-Moghadam; D Seidel
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.

Authors:  C M Ferrier; H H de Witte; H Straatman; D H van Tienoven; W L van Geloof; F J Rietveld; C G Sweep; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.